title: Role of concomitant chemoradiation in locally advanced head and neck cancers.
abstract: Standard therapy for advanced head and neck cancer consists of a combination of surgery and radiation. However, survival of this patient population has not improved during the past 20 years. Many different multimodality treatment schedules have been proposed, and chemotherapy is often used with the intent of organ preservation. The present study was intended to establish the efficacy of concomitant chemoradiation with a single agent carboplatin in advanced head and neck cancers.The objectives were to investigate the feasibility of concomitant administration of carboplatin, monitor acute toxicity during radiotherapy, and determine subacute side effects, such as wound healing following surgery after chemoradiotherapy. A prospective study was conducted wherein a total of 40 patients with stage III and IV squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx were enrolled. All patients were treated with external beam radiotherapy and weekly carboplatin area under curve (AUC of 5). Radiotherapy was given in single daily fractions of 1.8-2 grays (Gy) to a total dose of 66-72 Gy. Salvage surgery was performed for any residual or recurrent locoregional disease. Neck dissection was recommended for all patients with neck disease showing less than a complete response after chemoradiation. A total of 40 patients were enrolled of whom 32 were males and 8 were females. Highest incidence of cancer was seen in the 5th-6th decades of life with a median age of 47.7 years. Oropharyngeal tumours constituted a maximum of 21 patients followed by hypopharynx in 10, larynx in 7 and oral cavity in 2. 80% of the patients had a neck node on presentation of which 40% had N2-N3 nodal status. TNM staging revealed that 58% of patients were in stage III and 43% in stage IV. Evaluation of acute toxicity revealed that 50% had grade II mucositis, 25% grade III mucositis, 2.5% grade IV mucositis. 50% of patients had grade I skin reactions, 65% of patients had grade I thrombocytopenia, and 24% of patients had grade I anaemia. After completion of treatment 65% of patients had complete response at the primary and regional sites, and 35% of patients had a partial response of whom 23% underwent neck dissection and 5% of them underwent salvage surgery at the primary site. At the end of one year there were six deaths and four recurrences and 70% were free of disease. Concurrent chemoradiation with carboplatin provided good locoregional control for locally advanced head and neck cancers. This regimen, although toxic, is tolerable with appropriate supportive intervention. Primary site conservation is possible in many patients. Chemoradiotherapy appears to have an emerging role in the primary management of head and neck cancers.
authors.affiliation: Department of Otorhinolaryngology and Head and Neck Surgery, Father Muller Medical College, Mangalore, India E-mail : Savita_menezes@yahoo.com.
authors.forename: Savita
authors.initials: S
authors.lastname: Lasrado
authors.forename: Kuldeep
authors.initials: K
authors.lastname: Moras
authors.forename: George Jawahar Oliver
authors.initials: GJ
authors.lastname: Pinto
authors.forename: Mahesh
authors.initials: M
authors.lastname: Bhat
authors.forename: Sanath
authors.initials: S
authors.lastname: Hegde
authors.forename: Brijesh
authors.initials: B
authors.lastname: Sathian
authors.forename: Neil Aaron
authors.initials: NA
authors.lastname: Luis
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D052016:Mucositis / Q000473:pathology; D009333:Neck / Q000473:pathology / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D016879:Salvage Therapy; D000077195:Squamous Cell Carcinoma of Head and Neck; D015996:Survival Rate; D013921:Thrombocytopenia / Q000473:pathology; D014945:Wound Healing
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin